It recorded a net loss of $21.8 million. Diluted earnings per share were -$8.35.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development |
13
-24.4%
|
11
-56.0%
|
26
-4.1%
|
27
+49.3%
|
18
+3.9%
|
18
+73.4%
|
10
+12.7%
|
9
+31.6%
|
7
-27.8%
|
9
+99.3%
|
5
-7.9%
|
| Selling, general and administrative |
10
-51.0%
|
11
-55.2%
|
26
+119.3%
|
12
+10.9%
|
11
+61.2%
|
7
+27.1%
|
5
-0.6%
|
5
+7.5%
|
5
+16.6%
|
4
-12.0%
|
5
+38.4%
|
| Operating income |
-24
+38.9%
|
-23
+55.6%
|
-52
-32.9%
|
-39
-35.2%
|
-29
-19.4%
|
-24
-57.8%
|
-15
-7.8%
|
-14
-6.4%
|
-13
+2.0%
|
-14
-43.9%
|
-9
-7.9%
|
| Other income (expense) |
1
-87.3%
|
1
-83.6%
|
7
+287.7%
|
-4
-27.3%
|
-3
-34175.4%
|
0
-95.5%
|
0
+128.9%
|
0
-6.6%
|
0
+137.2%
|
0
-98.8%
|
3
+0.2%
|
| Pretax income |
—
|
-22
+51.0%
|
-45
-3.9%
|
-43
-34.5%
|
-32
|
—
|
—
|
—
|
—
|
—
|
—
|
| Income tax |
—
|
—
|
0
+210.0%
|
-0
+0.0%
|
-0
|
—
|
—
|
0
|
0
|
0
|
0
|
| Net income |
-22
+23.2%
|
-22
+51.1%
|
-45
-4.2%
|
-43
-34.5%
|
-32
-31.8%
|
-24
-59.8%
|
-15
-7.1%
|
-14
-6.4%
|
-13
+2.4%
|
-14
-119.4%
|
-6
-12.5%
|
| Basic EPS |
-3.77
+81.0%
|
-8.35
+77.1%
|
-36.52
-943.4%
|
-3.50
+22.4%
|
-4.51
-3.7%
|
-4.35
|
—
|
—
|
—
|
—
|
—
|
| Diluted EPS |
-3.77
+80.8%
|
-8.35
+80.1%
|
-41.89
-1096.9%
|
-3.50
+22.4%
|
-4.51
-3.7%
|
-4.35
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
6
+304.6%
|
3
+113.7%
|
1
-90.0%
|
12
+73.2%
|
7
+27.1%
|
6
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, diluted |
6
+299.9%
|
3
+110.7%
|
1
-89.9%
|
12
+73.2%
|
7
+27.1%
|
6
|
—
|
—
|
—
|
—
|
—
|
| Other measures | |||||||||||
| Depreciation and amortization |
—
|
0
-26.8%
|
0
+51.6%
|
0
+29.6%
|
0
|
—
|
0
+6.5%
|
0
+61.4%
|
0
-94.7%
|
2
+333.5%
|
0
-1.6%
|
| EBITDA |
—
|
-23
+55.8%
|
-51
-32.8%
|
-39
-35.2%
|
-29
|
—
|
-15
-7.9%
|
-14
-6.0%
|
-13
-9.9%
|
-12
-32.6%
|
-9
-8.3%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1279704
- Former names
- NOVELOS THERAPEUTICS, INC. (until Feb 11, 2014); COMMON HORIZONS INC (until Jun 2, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.